Nikhil Lalwani Sells 5,400 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the sale, the chief executive officer owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This trade represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $73.51 on Friday. The stock’s 50-day moving average price is $79.81 and its 200 day moving average price is $78.69. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.69 billion, a PE ratio of 15.84 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same period last year, the firm earned $1.80 EPS. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. KBC Group NV acquired a new position in ANI Pharmaceuticals during the first quarter worth $28,000. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. boosted its position in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $50,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.